Compare BridgeBio Pharma Inc (BBIO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Prospect Capital Corporation — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: BridgeBio Pharma Inc is far larger — about 14.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.03% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PSEC | |
|---|---|---|
Market Cap | $16.27B | $1.14B |
Sector | Health | Financials |
52-Week High | $90.17 | $3.47 |
52-Week Low | $44.81 | $2.15 |
Enterprise Value | $17.82B | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
PSEC trades at $2.25, down 0.44% recently, with a bearish technical signal and neutral oscillators. The company shows mixed fundamentals with a low P/B of 0.39 and consistent earnings beats in recent quarters, but negative revenue of -$407M and net income margin of -495.94% for 2025 highlight financial stress. Recent news includes a new investment in ShipOffers and ongoing dividend payments, though sentiment is cautious amid a deep discount to NAV.
The outlook remains challenging due to persistent negative revenue and high yield risks, but the valuation discount and earnings beats offer potential for value investors. Key risks include further NAV erosion and dividend sustainability, while institutional sentiment is divided with 25% buy ratings against 55% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
